NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
35
Data completeness
6/8 — Strong
PRISTIQ (desvenlafaxine succinate) by Pfizer is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Approved for major depressive disorder, vasomotor symptoms. First approved in 2008.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRISTIQ is an oral extended-release tablet containing desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor (SNRI) approved by Pfizer in 2008. It is indicated for major depressive disorder and works by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system. The active ingredient is the active metabolite of the parent compound venlafaxine.
$0.007BPart D
LOE Approaching1.2 years to LOEWith LOE approaching in 2027, PRISTIQ represents a mature brand in managed decline, likely with consolidated support teams focused on maximizing remaining market exclusivity.
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.
Indications (2)
Worked on PRISTIQ at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.